Computational fluid dynamics modeling, a novel, and effective approach for developing scalable cell therapy manufacturing processes

Induced pluripotent stem cells (iPSCs) hold great potential to generate novel, curative cell therapy products. However, current methods to generate these novel therapies lack scalability, are labor‐intensive, require a large footprint, and are not suited to meet clinical and commercial demands. Therefore, it is necessary to develop scalable manufacturing processes to accommodate the generation of high‐quality iPSC derivatives under controlled conditions. The current scale‐up methods used in cell therapy processes are based on empirical, geometry‐dependent methods that do not accurately represent the hydrodynamics of 3D bioreactors. These methods require multiple iterations of scale‐up studies, resulting in increased development cost and time. Here we show a novel approach using computational fluid dynamics modeling to effectively scale‐up cell therapy manufacturing processes in 3D bioreactors. Using a GMP‐compatible iPSC line, we translated and scaled‐up a small‐scale cardiomyocyte differentiation process to a 3‐L computer‐controlled bioreactor in an efficient manner, showing comparability in both systems.

[1]  S. Gerecht,et al.  Scalable expansion of human induced pluripotent stem cells in the defined xeno-free E8 medium under adherent and suspension culture conditions. , 2013, Stem cell research.

[2]  Don Paul Kovarcik,et al.  cGMP-Manufactured Human Induced Pluripotent Stem Cells Are Available for Pre-clinical and Clinical Applications , 2015, Stem cell reports.

[3]  Robert Zweigerdt,et al.  Suspension culture of human pluripotent stem cells in controlled, stirred bioreactors. , 2012, Tissue engineering. Part C, Methods.

[4]  Todd C McDevitt,et al.  Aggregate formation and suspension culture of human pluripotent stem cells and differentiated progeny. , 2016, Methods.

[5]  M. Rao,et al.  Human-Induced Pluripotent Stem Cells Manufactured Using a Current Good Manufacturing Practice-Compliant Process Differentiate Into Clinically Relevant Cells From Three Germ Layers , 2018, Front. Med..

[6]  Sean P. Palecek,et al.  Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling , 2012, Proceedings of the National Academy of Sciences.

[7]  Robert Zweigerdt,et al.  Controlling Expansion and Cardiomyogenic Differentiation of Human Pluripotent Stem Cells in Scalable Suspension Culture , 2014, Stem cell reports.

[8]  T. Ichisaka,et al.  Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.

[9]  Robert Zweigerdt,et al.  Scalable expansion of human pluripotent stem cells in suspension culture , 2011, Nature Protocols.

[10]  E. A. Reece,et al.  High glucose suppresses embryonic stem cell differentiation into cardiomyocytes , 2016, Stem Cell Research & Therapy.

[11]  Vincent C. Chen,et al.  Scalable GMP compliant suspension culture system for human ES cells. , 2012, Stem cell research.

[12]  P. Schultz,et al.  Stepwise Chemically Induced Cardiomyocyte Specification of Human Embryonic Stem Cells , 2011 .

[13]  Vincent C. Chen,et al.  The suspension culture of undifferentiated human pluripotent stem cells using spinner flasks. , 2015, Methods in molecular biology.

[14]  Breanna S Borys,et al.  Scale-up of embryonic stem cell aggregate stirred suspension bioreactor culture enabled by computational fluid dynamics modeling , 2018 .

[15]  Ivana Knezevic,et al.  Report of the international conference on manufacturing and testing of pluripotent stem cells. , 2018, Biologicals : journal of the International Association of Biological Standardization.

[16]  J. Itskovitz‐Eldor,et al.  Suspension Culture of Undifferentiated Human Embryonic and Induced Pluripotent Stem Cells , 2010, Stem Cell Reviews and Reports.

[17]  D. Rancourt,et al.  Optimizing Human Induced Pluripotent Stem Cell Expansion in Stirred-Suspension Culture. , 2017, Stem cells and development.

[18]  V. Natarajan,et al.  Verification of energy dissipation rate scalability in pilot and production scale bioreactors using computational fluid dynamics , 2014, Biotechnology progress.

[19]  S. Reuveny,et al.  Unraveling the Inconsistencies of Cardiac Differentiation Efficiency Induced by the GSK3β Inhibitor CHIR99021 in Human Pluripotent Stem Cells , 2018, Stem cell reports.

[20]  D. Kehoe,et al.  Scalable stirred-suspension bioreactor culture of human pluripotent stem cells. , 2010, Tissue engineering. Part A.

[21]  Praveen Shukla,et al.  Development of a scalable suspension culture for cardiac differentiation from human pluripotent stem cells. , 2015, Stem cell research.

[22]  Antoine Heron,et al.  Scalable stirred suspension culture for the generation of billions of human induced pluripotent stem cells using single‐use bioreactors , 2018, Journal of tissue engineering and regenerative medicine.

[23]  K. McCloskey,et al.  Can shear stress direct stem cell fate? , 2009, Biotechnology progress.

[24]  Praveen Shukla,et al.  Chemically defined generation of human cardiomyocytes , 2014, Nature Methods.

[25]  M. Rao,et al.  Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications , 2016, Stem Cell Reviews and Reports.